

Proven efficacy across multiple studies³⁻⁶

Aleve® vs Tylenol®

- In a single-dose study, Aleve® was proven more effective[†] and clinically proven to last longer on pain than Tylenol® Extra Strength^{3,5}

[†]Based on clinical data from the first 6 hours after initial dosing.³

Aleve® vs opioid combination

- In a recent single-dose study, Aleve® was as effective^{||} as, lasted longer, and was better tolerated than hydrocodone plus acetaminophen (HYD+APAP)⁴

**NEW
DENTAL
STUDY**

Aleve® vs a different opioid combination

- In 2 separate studies with Aleve® vs acetaminophen plus codeine, Aleve® was proven to be stronger from the 3-hour mark onward and last longer⁵

Aleve® vs ibuprofen

- In 2 identical, non-prescription dose studies in patients with osteoarthritis (OA) of the knee, Aleve® provided more effective relief of pain at night than ibuprofen^{6,1}

Aleve® is indicated for minor aches and pains.¹

³A controlled, single-dose, clinical trial compared efficacy and duration of action of 440 mg Aleve® (n=92), 1000 mg acetaminophen (n=89), and placebo (n=45) in a randomized, double-blind, 12-hour study of patients with at least moderate pain after extraction of 3 or 4 third molars.³

^{||}In hours 0 to 4 of a single-dose dental study of Aleve® (440 mg), HYD+APAP (10 mg + 650 mg), or placebo.⁴

[†]Patients with mild to moderate OA of the knee were randomized to daily doses of naproxen sodium 660 mg, naproxen sodium 440 mg, ibuprofen 1200 mg, or placebo.⁵



Recommend the power of Aleve®

For long lasting pain relief

Powerful relief for minor OA pain²

- In a pooled analysis, Aleve® provided significant relief across all 6 efficacy endpoints (including pain at rest and pain at night)²

Proven more efficacious* than Tylenol®

^{*}Based on clinical data from the first 6 hours after initial dosing.

And as strong* as HYD+APAP⁴

- In a recent single-dose dental study, Aleve® was as effective,[†] lasted longer, and was better tolerated⁴

Trusted by patients for 26 years for pain relief

168 million patients used naproxen sodium in the last year alone⁵

Strong safety profile when used as directed^{5,9,10}

[†]In hours 0 to 4 of a single-dose dental study of Aleve® (440 mg), hydrocodone plus acetaminophen (HYD+APAP) (10 mg + 650 mg), or placebo.⁴

**ALEVE® IS THE #1 ORTHOPEDIC
SURGEON-RECOMMENDED OTC
BRAND FOR MINOR ARTHRITIC PAIN⁵**



Use as directed.



Visit aleve.com/healthcare-professionals to download coupons, see clinical studies, and order additional free samples.

References: 1. Aleve® Caplets. Drug facts. Bayer HealthCare; April 2018. 2. Couto A, Troullos E, Moon J, Paredes-Diaz A, An R. Analgesic efficacy and safety of non-prescription doses of naproxen sodium in the management of moderate osteoarthritis of the knee or hip. *Curr Med Res Opin.* 2018;34(10):1747-1753. doi:10.1080/03007995.2018.1437029 3. Kirsch TA, Halladay SC, Hormel PC. A single-dose, double-blind comparison of naproxen sodium, acetaminophen, and placebo in postoperative dental pain. *Clin Ther.* 1994;16(3):394-404. 4. Cooper SA, Desjardins PJ, Bertoch T, et al. Analgesic efficacy of naproxen sodium versus hydrocodone/acetaminophen in acute postsurgical dental pain: a randomized, double-blind, placebo-controlled trial. *Postgrad Med.* 2021. doi:10.1080/00325481.2021.2008180 5. Data on file. Bayer HealthCare. 6. Schiff M, Minic M. Comparison of the analgesic efficacy and safety of non-prescription doses of naproxen sodium and ibuprofen in the treatment of osteoarthritis of the knee. *J Rheumatol.* 2004;31(7):1373-1383. 7. American Academy of Orthopaedic Surgeons. Treatment of osteoarthritis of the knee—2nd edition. Evidence-based clinical practice guideline. Accessed January 24, 2022. <https://www.aaos.org/globalassets/quality-and-practice-resources/osteoarthritis-of-the-knee/osteoarthritis-of-the-knee-2nd-edition-clinical-practice-guideline.pdf> 8. Kolasinski SL, Neogi T, Hochberg MC, et al. 2019 American College of Rheumatology/Arthritis foundation guideline for the management of osteoarthritis of the hand, hip, and knee. *Arthritis Rheumatol.* 2020;72(2):220-233. doi:10.1002/art.41142 9. Kyeremateng K, Troullos E, Paredes-Diaz A. Safety of naproxen compared with placebo, ibuprofen and acetaminophen: a pooled analysis of eight multiple-dose, short-term, randomized controlled studies. *Curr Med Res Opin.* 2019;35(10):1671-1676. doi:10.1080/03007995.2019.1612338 10. DeArmond B, Francisco CA, Lin J-S, et al. Safety profile of over-the-counter naproxen sodium. *Clin Ther.* 1995;17(4):587-601. doi:10.1016/0149-2918(95)80036-0

Aleve, Bayer, and the Bayer Cross are registered trademarks of Bayer. All rights reserved. Unless otherwise indicated, all trademarks are owned by Bayer and its affiliates, or licensed for its use. © 2022 Bayer March 2022 CH-20220201-84



For your patients with minor osteoarthritis (OA) pain

Recommend the POWER of Aleve®

For long lasting pain relief



Use as directed.

**SEE NEW
CLINICAL
DATA INSIDE**


Aleve® is an OTC pain reliever indicated for temporary relief of minor aches and pains including arthritis pain, headache, muscular aches, and toothache.¹

The growing body of evidence shows²⁻⁶

Aleve[®] is proven to provide tough pain relief²

In a pooled analysis of adults with OA, Aleve[®] significantly reduced OA pain in the hip and knee²

Aleve[®] provided significant relief across all efficacy endpoints ($P < 0.05$)^{2*}



CHANGE IN EFFICACY FROM BASELINE TO 7 DAYS IN PATIENTS WITH MILD TO MODERATE OA

In the same analysis

Aleve[®] provided significantly greater OA pain relief[†] for patients ≥ 65 years of age ($P < 0.05$) in^{2,*}:

- Pain on passive motion
- Pain during the day and pain at night
- Pain on weight bearing

OA, osteoarthritis.

*Results of a post hoc pooled analysis evaluating the efficacy and safety of Aleve[®] for short-term use in patients with OA of the knee or hip. In 4 multicenter, multidose, randomized, parallel, double-blind, placebo-controlled studies, Aleve[®] (age-based dosing regimen: < 65 years, 660 mg/day; ≥ 65 years, 440 mg/day) or placebo was administered over 7 days. Data at baseline and after 7 days in 818 patients who received Aleve[®] or placebo ($n=409$ in each group) were pooled and analyzed.

[†]Compared with placebo.²



Major association guidelines recommend NSAIDs like naproxen sodium, the active ingredient in Aleve[®], as a first-line treatment for OA pain

American Academy of Orthopaedic Surgeons

- Strongly recommends for knee OA pain⁷

American College of Rheumatology

- Strongly recommends for knee, hip, and/or hand OA⁸
 - Acetaminophen is conditionally recommended for patients with knee, hip, and/or hand OA pain⁸

Proven safety profile when used as directed

- In a large meta-analysis of pooled safety data from Aleve[®] clinical trials, adverse events for OTC Aleve[®] were not significantly different than placebo⁹
- In a separate analysis, adverse events rates for naproxen/naproxen sodium were shown to be no worse than placebo, with most patients (83%) treated with naproxen/naproxen sodium reporting no side effects¹⁰
- The most commonly reported adverse events were headache, nausea, and somnolence
- In combined reporting from clinical trial data, very rare incidence ($< 0.01\%$) of serious or life-threatening hepatic adverse events when taken as directed⁵

SAFELY RELIEVES PAIN WHEN USED AS DIRECTED^{5,9,10}



Use as directed.